Active Biotech develops innovative pharmaceuticals that modulate the body's own immune system.We focus on widespread diseases for which a tremendous need is felt for new and more effective treatments.

2008-08-06	Active Biotech AB Interim Report January-June 2008
2008-07-23	Tomas Leanderson appointed new President & CEO for Active Biotech
2008-07-16	TEVA ENROLLS PATIENTS FOR A SECOND LARGE GLOBAL PHASE III TRIAL OF ORAL LAQUINIMOD
2008-06-30	Number of shares and votes in Active Biotech
2008-06-24	RhuDex® Achieves Positive Results in Clinical Phase IIa Trial
2008-06-20	Active Biotech's Novel MS Compound laquinimod Featured in the Scientific Publication The Lancet

Advanced search

RhuDex;

Read press releases from MediGene >>

RhuDex is a CD 80 antagonist that was out-licensed from Active Biotech to MediGene (Avidex) in year 2002. MediGene has the exclusive license to develop and commercialize RhuDex. RhuDex originates from a unique substance group that is not related to any other of Active Biotech's compounds.

Interview with Sven Andréasson, President & CEO

Annual Report 2007

Read the report here >>

Rodman and Renshaw 5th Global Healthcare Conference

May 19-20, 2008

Listen to the presentation >>

Annual General Meeting - May 7, 2008

Subscribe to press releases from Active Biotech

Fill in form >>

Active Biotech AB, Scheelevägen 22, P.O. Box 724, SE-220 07 Lund, Sweden, Telephone +46 46 19 20 00